Avisi technologies is a pre-clinical stage company developing a nanotechnology-enabled defense against blindness from glaucoma.

Avisi is a pre-clinical stage medical devices company developing VisiPlate, a nanotechnology-enabled ocular implant for treating glaucoma. VisiPlate is 20x thinner than a human hair and aims to safely reduce eye pressure in glaucoma patients, while minimizing the risk of patient discomfort and device failure from scarring.

Industry: Health
Status: Active

Contact Information


Rui Jing Jiang

Co-Founder and CEO

Brandon Kao

Co-Founder and CTO